News Release

Novel approach for rapid identification and development of malaria vaccines

Peer-Reviewed Publication

PLOS

Malaria is the world’s most frequent parasitic disease, affecting more than 100 countries in the tropical zones, mostly in Africa, and 40% of the world population, with more than a million deaths per year. As a consequence countries affected by malaria also tend to be economically disadvantaged. The development of a vaccine constitutes a major scientific and health challenge. Research conducted at the Biochemistry Department of the University of Lausanne, Switzerland, has established a novel approach for the rapid discovery and development of vaccine candidates.

The malaria parasites injected through the bite of an infected female mosquito first develop in the liver and then in the blood. Clinical symptoms are associated with the latter stage and no vaccine is currently available. The development of an antibody-based vaccine to stop the proliferation of the parasite in the blood is thus clearly needed. The few candidates already tested or in the development process were identified over 20 years ago.

Taking advantage of the recently sequenced parasite genome, together with bioinformatics and peptide synthesis, Dr Giampietro Corradin’s group, University of Lausanne, Switzerland, in close collaboration with Dr Andrey Kajava, University of Montpellier, France, has developed a novel approach for the rapid identification of malaria vaccine candidates. This approach is based on a bioinformatics selection of hundreds of short ?-helical coiled coil protein segments (30-40 amino acids long) which are able to maintain their conformation once they are chemically synthesized. In the first round of selection, all of 95 peptides synthesized were shown to be recognized by sera from malaria immune donors. Purified human antibodies specific to a dozen of these peptides could effectively inhibit parasite growth in vitro. Due to the rapidity of the identification and manufacturing process, time and cost to enter new vaccine candidates in clinical trials can be drastically reduced.

###

Disclaimer

The following press release refers to an upcoming article in PLoS ONE. The release has been provided by the article authors and/or their institutions. Any opinions expressed in this are the personal views of the contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.

This research was conducted in collaboration with the Pasteur Institute, Paris, France, the Swiss Tropical Institute, Basel, Switzerland, CNLRP, Ouagadougou, Burkina Faso and the University of Valle, Cali, Colombia.

The paper appears in the July 25 issue of the online, open-access journal PLoS ONE.

Contact:
Giampietro Corradin (corresponding author)
University of Lausanne
Email: Giampietro.Corradin@unil.ch

Citation: Villard V, Agak GW, Frank G, Jafarshad A, Servis C, et al (2007) Rapid Identification of Malaria Vaccine Candidates Based on a-Helical Coiled Coil Protein Motif. PLoS ONE 2(7): e645. doi:10.1371/journal.pone.0000645

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://www.plosone.org/doi/pone.0000645

PRESS ONLY PREVIEW: http://www.plos.org/press/pone-02-07-corradin.pdf


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.